lecanemab alzheimer news

European regulators green light new Alzheimer's drug

Hosted on MSN · 14h

European regulators green light new Alzheimer's drug after first rejecting it

European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews

The Associated Press - Busines… · 1d

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

DPA International on MSN · 1d

EU regulator reverses decision to block Alzheimer's drug lecanemab

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.

Worldcrunch on MSN8h

Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Medscape8h

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

ALZFORUM1d

Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Medpage Today on MSN4d

Alzheimer's Data Withdrawn

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results